Related by context. All words. (Click for frequent words.) 73 Phase IIIb clinical 73 phase IIb trial 70 phase IIb clinical 70 Phase #b/#a 69 Phase Ib study 69 Phase IIb clinical trials 69 Phase 1b trial 69 Phase IIa trial 68 Phase IIB 68 Phase 2a trial 68 phase IIa clinical 68 RE LY ® 68 phase IIa 68 ADAGIO study 68 lomitapide 68 phase IIb 67 RSD# oral 67 Phase IIa trials 67 registrational 67 Phase 2b study 67 vidofludimus 66 pharmacokinetic PK study 66 CIMZIA ™ 66 Phase IIb trials 66 SUCCEED trial 66 cannabinor 66 clevidipine 66 clinical trials 66 elotuzumab 66 placebo controlled clinical trials 66 SYMMETRY trial 66 EndoTAG TM -1 66 Phase Ib clinical 66 Zenvia Phase III 66 Phase Ib 66 clinical trial 66 CHAMPION PCI 66 Phase 2b trial 66 placebo controlled Phase III 66 INCB# [001] 66 Androxal TM 66 Phase #/#a 66 phase IIIb 66 viral kinetic 65 rALLy trial 65 placebo controlled clinical 65 AZILECT ® 65 Phase IIb trial 65 OLYMPIA registry 65 GENASIS trial 65 forodesine 65 PEARL SC 65 SNT MC# 65 Phase Ib II 65 PROSTVAC TM 65 HORIZONS AMI trial 65 nonclinical studies 65 riociguat 65 preclinical efficacy 65 pharmacokinetic studies 65 CytoFabTM 65 brivaracetam 65 multicenter trials 65 Phase 1a clinical 65 pivotal bioequivalence 65 Dacogen injection 65 Phase III trials 65 multicenter Phase II 65 oral ridaforolimus 65 randomized Phase 2b 64 bicifadine 64 thorough QT 64 DAPT 64 MERLIN TIMI 64 Traficet EN 64 Phase IIb III 64 BLA filing 64 budesonide foam 64 confirmatory Phase III 64 AeroLEF TM 64 PRECISE trial 64 alvespimycin 64 MAA submission 64 canakinumab 64 YONDELIS 64 Plicera 64 NATRECOR R 64 Phase IIb clinical 64 bardoxolone 64 lumiliximab 64 deforolimus 64 CRLX# 64 Liprostin 64 EVIZON 64 TG MV 64 multicenter clinical trials 64 clinical 64 velafermin 64 GFT# 64 OHR/AVR# 64 phase IIb study 64 EchoCRT 64 IPL# 64 confirmatory clinical 64 Phase 2a clinical 64 INTERCEPT platelets 64 NP2 Enkephalin 64 diabetic neuropathic pain 64 viral kinetics 64 TACI Ig 64 IND submission 64 AIM HIGH 64 Elocalcitol 64 APTIVUS 64 nalbuphine ER 64 VITAL Trial 64 RE LY trial 64 teduglutide 64 registrational trial 63 CIMZIA TM certolizumab pegol 63 Urocortin 2 63 HCV SPRINT 63 C1 INH 63 BRIM3 63 ganetespib 63 cardio renal 63 Azedra 63 Phase IIb 63 dirucotide 63 ENDEAVOR clinical 63 recombinant factor VIIa 63 Thorough QT 63 Renal Cell Carcinoma RCC 63 HGS# 63 LibiGel Phase III 63 PSMA ADC 63 dose cohort 63 PDE# inhibitors 63 dosing cohort 63 PRTX 63 ELACYT 63 LUMINATE 63 ataluren 63 oral deforolimus 63 Phase III Clinical Trials 63 CR# vcMMAE 63 HCV RESPOND 2 63 Phase IIIb study 63 dosage regimens 63 ANCHOR trial 63 PRT# 63 PSN# [002] 63 Phase #/#a trial 63 AZILECT R 63 immatics 63 IMA# 63 budesonide MMX Phase III 63 tesmilifene 63 Phase 2b clinical 63 PROactive study 63 recurrent glioma 63 Actimmune ® 63 JAK inhibitor 63 ONCONASE R 63 trastuzumab emtansine T DM1 63 inhibitor RG# 63 Phase IIIb 63 Altastaph 63 GAMMAGARD 63 trials RCTs 63 PREOS R 63 clinicaltrials 63 NO# [002] 63 ularitide 63 ORENCIA R 63 midstage trials 63 Clinicaltrials.gov 63 GLP toxicology studies 63 desvenlafaxine succinate 63 eniluracil 63 ADVANCE PD 62 NCCTG 62 Phase III clinical 62 omecamtiv mecarbil 62 preclinically 62 prospective observational 62 ASSERT trial 62 pharmacokinetic PK 62 rindopepimut 62 Betaferon ® 62 Phase IIa clinical 62 Icatibant 62 Phase III clinical trials 62 Quinamed 62 ACZ# 62 EMPHASIS HF trial 62 ENDEAVOR IV 62 prospective multicenter study 62 trastuzumab Herceptin ® 62 lorcaserin Phase 62 Symadex 62 preclinical toxicology 62 Genz # 62 BrachySil TM 62 Bicifadine 62 ONTARGET 62 enzastaurin 62 Asentar 62 EDEMA3 trial 62 GRAVITAS trial 62 phase IIb III 62 ProSavin 62 Phase III randomized controlled 62 Cimzia TM 62 Cethrin 62 ancrod 62 opioid induced bowel dysfunction 62 Valdoxan 62 Viprinex TM 62 multicenter Phase 62 ACOMPLIA R 62 AEGR 62 microplasmin Phase III 62 Phase III registrational 62 Alvesco R 62 CIMZIA TM 62 Phase 2a clinical trials 62 RhuDex 62 NABTT 62 placebo controlled trials 62 Dose escalation 62 alvimopan 62 methylnaltrexone 62 lintuzumab 62 Phase 1a 62 eTag assays 62 preclinical pharmacokinetic 62 oral methylnaltrexone 62 ORMD 62 glucokinase activator 62 fosbretabulin 62 CINTREDEKIN BESUDOTOX 62 midstage clinical 62 Phase III Clinical Trial 62 eculizumab therapy 62 investigational therapies 62 OvaRex R 62 APEX AMI trial 62 MEK inhibitor 62 HuMax EGFr 62 BARI 2D 62 Triolex 62 OvaRex ® MAb 62 EGS# 62 NTx ® -# 62 randomized Phase IIb 62 Aloxi injection 62 LEUKINE 62 ABSORB trial 62 Meta analyzes 62 CCX# 62 UVIDEM 62 recurrent herpes labialis 62 PHX# 62 CRMD# 62 MEND CABG 62 Octreolin 62 Phase #b/#a trial 62 mg/m2 cohort 62 Virulizin ® 62 sunitinib malate 62 THALOMID 62 Exherin TM 62 HPTN 62 HeFH 62 CBLC# 62 NeuroStar TMS Therapy 62 BioSTAR R 62 cystinosis patients 62 torezolid phosphate 62 aplindore 62 optimal dosing 62 Phase IIa 62 RenalGuard System TM 62 CALGB 62 Zemplar Capsules 62 crizotinib PF # 62 oral salmon calcitonin 62 ASPIRE HIGHER 62 MAGE A3 ASCI 62 randomized controlled clinical trials 62 SEPET TM 62 dose escalation Phase 62 prospective multicentre 61 TBC# 61 oral FTY# 61 randomized multicenter Phase III 61 AERx iDMS 61 tolevamer 61 pitavastatin 61 eosinophilic asthma 61 PreCISe study 61 teriflunomide 61 Diamyd ® 61 BLA submission 61 Raptiva ® 61 elacytarabine 61 FOLOTYN ® 61 OMAPRO 61 pharmacokinetic pharmacodynamic 61 randomized Phase III 61 CLARITY study 61 sitaxsentan 61 alagebrium 61 Cethromycin 61 glatiramer acetate 61 ENGAGE AF TIMI 61 Phase IIa clinical trials 61 DEB# 61 MYDICAR 61 ISIS # 61 Voraxaze ™ 61 ATL# [001] 61 NDA resubmission 61 methylnaltrexone tablet 61 PRIMO CABG 61 pharmacokinetic PK profile 61 tanespimycin 61 Chrysalin 61 Golimumab 61 PREGNANT Study 61 candidate CRLX# 61 trodusquemine 61 Ostarine 61 dexanabinol 61 QTinno TM 61 TELINTRA 61 MADIT CRT trial 61 dose cohorts 61 EOquin TM 61 sJIA 61 Protexia ® 61 NLX P# 61 Edwards SAPIEN valve 61 STRIDE PD 61 Phase 1b 61 ponatinib 61 Surfaxin LS 61 Tasimelteon 61 COMFORT II 61 RESOLUTE clinical 61 MORAb 61 relapsed MM 61 Fibrillex TM 61 BioNumerik 61 ALISTA 61 blinded randomized placebo controlled 61 posaconazole 61 Cimzia ® certolizumab pegol 61 Zometa zoledronic acid 61 retrospective observational study 61 ILLUMINATE 61 Proellex TM 61 ulimorelin 61 PEG PAL 61 ruxolitinib 61 Microplasmin 61 postapproval 61 HF ACTION 61 IIa trials 61 REG1 61 GED aPC 61 eprotirome 61 Allovectin 7 ® 61 PROMACTA 61 AMPAKINE CX# 61 lupus nephritis 61 Blinatumomab 61 Phase IIIB IV 61 APTIVUS r 61 Serdolect ® 61 Corlux 61 Protelos 61 Phase 1b dose escalation 61 Cleviprex TM clevidipine 61 REMINYL ® 61 phase Ib 61 masitinib 61 noninfectious uveitis 61 Hedgehog antagonist 61 dose escalation 61 Dextofisopam 61 evaluating REVLIMID 61 Zenvia ™ 61 atacicept 61 GALNS 61 pharmacogenetic testing 61 DXL# 61 TQT studies 61 intravenous methylnaltrexone 61 tramiprosate Alzhemed TM 61 obatoclax 61 Stimuvax R 61 Tracleer R 61 TRISENOX 61 CUSTOM III 61 Alzhemed TM 61 pomalidomide 61 VADT 61 AZD# TC 61 Clonicel 61 VALOR trial 61 TKM ApoB 61 postmenopausal osteoporotic women 61 MoxDuo TM IR 61 insulin detemir 61 NOX E# 61 Virulizin R 61 acyclovir Lauriad ® 61 EXPAREL ™ 61 Aurexis 61 Phase Ia 61 ENESTnd 61 DermaVir Patch 61 TOLAMBA 61 cMET 61 angiographic outcomes 61 CTAP# Capsules 61 ongoing Phase IIIb 61 acyclovir Lauriad R 61 ALN TTR# 61 MoxDuo 61 rFIXFc 61 Nanobody ® 61 HQK 61 sipuleucel T 61 intermittent dosing 61 Phase 2a 61 Cytolin 60 placebo controlled Phase 60 MIST II 60 multicenter randomized placebo controlled 60 dose escalation phase 60 cangrelor 60 synthetic retinoid 60 EDEMA3 60 dirucotide MBP# 60 Cloretazine 60 davunetide intranasal AL 60 multicenter clinical 60 Tesmilifene 60 NV1FGF 60 MYCAMINE 60 SABCS 60 pharmacodynamic effects 60 oral taxane 60 Spiegelmer ® 60 PXD# 60 unblinding 60 IRX 2 60 JAK2 inhibitor 60 ACCLAIM II 60 Arikace 60 placebo controlled studies 60 multicenter randomized clinical 60 ostarine 60 CoFactor 60 MYDICAR ® 60 pivotal Phase III 60 GRN# 60 Pivotal Trial 60 Betaferon R 60 doxorubicin docetaxel 60 AEG# 60 multicenter study 60 heterozygous FH 60 AOD# [002] 60 Nexavar sorafenib 60 HCD# [002] 60 PREOS 60 Orazol 60 Pivotal Clinical Trial 60 Phase 2b 60 rALLy clinical trial 60 MBP# [001] 60 Ketotransdel 60 NSABP B 60 liprotamase 60 Urocidin 60 DDP# 60 PFO migraine 60 Phase 2a Study 60 Aryplase 60 dosing cohorts 60 active comparator 60 lorvotuzumab mertansine 60 DSMB 60 Phase #b/#a clinical 60 Amigal 60 Tanespimycin 60 Phase III TRIST 60 postoperative ileus POI 60 Velcade bortezomib 60 standard chemotherapy regimen 60 Acute Ischemic Stroke 60 Alocrest 60 prospective multicenter 60 PEG SN# 60 ISTODAX 60 rEV# 60 intradermal injections 60 INCB# [003] 60 PROPEL trial 60 Angiox R 60 dose titration 60 RGB # 60 Azilect ® 60 Glypromate 60 COPAXONE R 60 Dalbavancin 60 GOUT 60 AGILECT R 60 rFVIIa 60 HuMax CD4 60 relapsed MCL 60 EOquin 60 IMC #B 60 Nanobodies ® 60 HDL Selective Delipidation 60 RELOVAIR ™ 60 tranilast 60 SAR# [004] 60 RezularTM 60 USL# 60 PMA submission 60 antihypertensive therapy 60 peg interferon 60 Ilaris 60 BCIRG 60 ESBA# 60 P#X# antagonist 60 HuMax CD# 60 TLK# 60 pradefovir 60 ALTU 60 dacetuzumab 60 trabedersen 60 oxymorphone ER 60 Ocrelizumab 60 sNDA submission 60 PRX # 60 Phase #/#a clinical 60 inhaled AAT 60 Ophena 60 null responder HCV 60 REVEAL Registry 60 PANVAC VF 60 double blinded randomized 60 ZOLINZA 60 PRE SURGE 60 antibody MAb 60 Ozarelix 60 APTIMA HPV assay 60 ALGRX 60 Pimavanserin 60 balsalazide tablet 60 indiplon capsules 60 DU #b 60 EndoTAG TM 60 WILEX 60 favorable pharmacokinetic profile 60 midstage studies 60 phase III ACCLAIM 60 pharmacodynamic PD 60 Neuradiab 60 R#/MEM # 60 Gabapentin GR 60 pharmacoeconomic analysis 60 Reverset 60 Vasogen Celacade 60 Dr. Fehlings 60 senicapoc 60 R#/MEM 60 tipranavir 60 axitinib 60 abiraterone acetate 60 Itopride 60 GLP toxicology 60 PRADAXA 60 chronic myocardial ischemia 60 CERVARIX 60 denosumab oncology 60 vismodegib 60 PLCO 60 Study #CL# 60 BEXXAR 60 ToGA 60 multicenter Phase III 60 ascending dose 60 Thorough QT TQT 60 CAPHOSOL 60 tremelimumab 60 PEGPH# 60 randomized clinical trials 60 Prostate AdenoCarcinoma Treatment 60 pertuzumab 60 MNTX 60 pharmacodynamic parameters 60 TAXUS TM 60 bioequivalency 60 Vernakalant 60 Ovarian PLCO Cancer 60 APTIVUS R 60 CEQ# 60 Trandolapril 60 TPI ASM8 60 INT# [002] 60 enoximone 60 Insulin PH# 60 HSCT 60 selective androgen receptor modulator 60 including eniluracil ADH 60 genotypic resistance 60 T1DM 60 Kepivance 60 multicenter placebo controlled 60 CINQUIL 60 Max Neeman 60 Bronchitol 60 phase Ib clinical 60 SUTENT ® 60 budiodarone 60 CYT# potent vascular disrupting 60 LHRH antagonists 59 ruboxistaurin 59 JP-#/fipamezole 59 symptomatic BPH 59 TEMSO 59 TMC# C# 59 Rasagiline 59 renal anemia 59 PDE4 inhibitor 59 pharmacodynamics 59 immunological diseases 59 BCR ABL inhibitor 59 goserelin 59 otelixizumab 59 incyclinide 59 Fodosine 59 HCV infected 59 LB# [003] 59 custirsen 59 pharmacokinetic 59 tasimelteon 59 Certican 59 decitabine 59 Tracleer r 59 Oglemilast 59 Phase III 59 pharmacokinetic characteristics 59 refractory CLL 59 severe hypercholesterolemia 59 MGd 59 PROSTVAC ® 59 AVADO 59 Allovectin 7 R 59 cortical stimulation 59 PRESEPT 59 MAXY alpha 59 Androxal ® 59 Fabry Disease 59 QNEXA 59 RRMS patients 59 Viprinex 59 AZX# 59 RIGScan CR 59 JAK inhibitors 59 VIR# 59 bardoxolone methyl 59 dose escalation clinical 59 oral rivaroxaban 59 Lu AA# 59 ROCKET AF 59 squalamine 59 vivo preclinical 59 interferon gamma 1b 59 rilonacept 59 topical NSAIDs 59 subanalysis 59 randomized multicenter trial 59 RhuDex ® 59 adecatumumab 59 cinacalcet 59 Oral Insulin Capsule 59 MEND CABG II 59 Candesartan 59 Trofex 59 AZOR 59 clazosentan 59 GSK# [001] 59 RAPTIVA 59 Vaxfectin R 59 protease inhibitor PI 59 paliperidone ER 59 Lupuzor 59 Heplisav 59 DCCR 59 arzoxifene 59 Rasilez Tekturna 59 NeuroVax 59 warfarin therapy 59 INTEGRILIN 59 non nucleoside HCV 59 prospectively defined 59 AQ4N 59 Randomized Evaluation 59 MoxDuo IR 59 OncoGel 59 NSABP 59 bortezomib Velcade 59 dextofisopam 59 Viramidine 59 Raptiva R 59 fluvastatin 59 prucalopride 59 recurrent malignant glioma 59 Squalamine 59 Factor VIIa 59 Omacetaxine 59 Phenoptin 59 timepoint 59 NEBIDO 59 metastatic RCC 59 Myocet 59 REVIVE Diabetes 59 PD LID 59 APPRAISE 59 Myelodysplastic syndromes MDS 59 CLL8 59 fidaxomicin Phase 3 59 Evoltra ® 59 QLT# 59 multicentre study 59 confirmatory Phase 3 59 EFAPROXYN 59 ROTATEQ 59 interferon ribavirin 59 IL# PE#QQR 59 Twinrix 59 Phase 1b clinical 59 MOZOBIL 59 faropenem 59 BEXXAR therapeutic regimen 59 visilizumab 59 cat dander allergy 59 ELND# 59 Phase III pivotal 59 Evoltra TM 59 RE LY 59 Triapine R 59 HuLuc# 59 epoetin alpha 59 treprostinil 59 APTIVUS ritonavir 59 randomized controlled trials RCTs 59 dopaminergic therapy 59 safinamide 59 BCX# 59 NATRECOR ® 59 RNAi therapeutic targeting 59 NUVIGIL 59 SparVax TM 59 COPAXONE ® 59 mertansine 59 Safinamide 59 Neulasta ® 59 PreCISe 59 Technosphere Insulin 59 trastuzumab DM1 T DM1 59 Phase 2b clinical trials 59 EORTC 59 GSK# [002] 59 DYNEPO 59 rALLy 59 Alfimeprase 59 BeneFIX 59 Elitek 59 AIR2 Trial 59 Sutent sunitinib 59 BST CarGel R 59 SYNTAX trial 59 novel VDA molecule 59 Telbivudine 59 Onconase 59 talactoferrin 59 Hepatocellular Carcinoma HCC 59 IIa trial 59 registrational trials 59 elagolix 59 CYPHER R Sirolimus eluting 59 GRNCM1 59 gefitinib Iressa 59 deferiprone 59 chemoprevention trials 59 efficacy tolerability 59 TMC# [002] 59 Civacir 59 TRO# 59 Xanafide 59 antiangiogenic agents 59 Cerashield 59 personalized immunotherapy 59 tecarfarin 59 farletuzumab 59 COSIRA trial 59 pramlintide 59 Q#IR 59 Chemophase 59 MEK inhibitor RDEA# 59 tumor necrosis 59 UPLYSO 59 Oral NKTR 59 VA# [002] 59 ARCOXIA 59 CardioFit 59 GetGoal Phase III 59 PLX cells 59 bioequivalence studies 59 ASCEND HF 59 pain palliation 59 omacetaxine mepesuccinate 59 aerosolized KL4 surfactant 59 COPERNICUS 59 maximally tolerated dose 59 Prosaptide 59 neratinib 59 ExTRACT TIMI 59 RLY# 59 blinded randomized controlled 59 EmbraceAC 59 omega interferon 59 PREZISTA r 59 relapsing remitting MS RRMS 59 Zoraxel 59 PRoFESS 59 hyperphenylalaninemia HPA due 59 micafungin 59 Tripep 59 OMNARIS Nasal Spray 59 antithrombotic therapy 59 IMPROVE HF 59 Serious Adverse Events 59 Locteron 59 MVax 59 ORENCIA ® 59 Celmed 59 EURIDIS 59 elective PCI 59 schizophrenia CIAS 59 docetaxel Taxotere ® 59 Acute Decompensated Heart Failure 59 QuickOpt 59 LymphoStat B 59 LCP AtorFen 59 Phase Ib clinical trials 59 daclizumab 59 FIRAZYR 59 specified primary endpoint 59 Clinical Antipsychotic Trials 59 Epanova 59 bendamustine 59 BNC# 59 reslizumab 59 Phase III HEAT 59 RG# ITMN 59 opioid analgesia 59 KAPIDEX 59 paclitaxel poliglumex 59 metastatic sarcomas 59 denufosol 59 prospective observational cohort 59 Veronate 59 postmarketing surveillance 59 apremilast 59 evaluating mipomersen 59 ER CHOP 59 Vimpat R 59 sapacitabine 59 Aflibercept 59 epigenetic therapies 59 COREG CR 59 LUX Lung 59 Phase 2a preventative 59 double blinded placebo 59 mRCC 59 renal denervation 59 cathepsin K inhibitor 59 NNR Therapeutics 59 celgosivir 59 ADHF 59 telaprevir VX 59 Pivotal Study 59 virological response 59 randomized blinded 58 afatinib 58 DP b# 58 nab paclitaxel 58 iPrEx 58 Desmoteplase 58 AVERROES 58 PEGylated interferon beta 1a 58 assessing T DM1 58 Allovectin 7 58 cobiprostone 58 SUTENT 58 Triapine 58 constipation OIC 58 ATACAND 58 GnRH antagonist 58 Instanyl 58 Anthim 58 iclaprim 58 fibromyalgia syndrome 58 European Sepsis Trial 58 desvenlafaxine 58 multicenter phase 58 mipomersen 58 EXPAREL 58 bevirimat Study 58 Multi MERCI 58 abstracts summarizing 58 Diamyd R 58 octreotide implant 58 genomic biomarker 58 Xelox 58 secondary efficacy endpoints 58 p# biomarker 58 ganaxolone 58 blinatumomab 58 CDP# 58 statistically significant efficacy 58 oral PTH 58 Sebivo 58 BRIM2 58 Solorel 58 RE COVER 58 Flutiform TM 58 nucleotide analog 58 CLORETAZINE TM VNP#M 58 ACAPODENE 58 punctal plug 58 glatiramer 58 IgG1 antibodies 58 vosaroxin 58 AGHD 58 SPIRIT FIRST 58 pyridostigmine 58 superficial bladder cancer 58 HGS ETR1 58 ofatumumab 58 MADIT CRT 58 randomized controlled Phase 58 FOLPI 58 HoFH 58 EMPHASIS HF 58 longitudinal cohort study 58 recurrent glioblastoma multiforme 58 ICA # 58 alemtuzumab Campath 58 oncolytic virus therapy 58 StemEx R 58 BARACLUDE R 58 Amrubicin 58 Lixivaptan 58 APEX PD 58 aleglitazar 58 Somatuline R Autogel R 58 Rebif ® 58 prospective randomized placebo 58 isavuconazole 58 ThGRF 58 NN# [001] 58 FAME Study 58 ALN TTR 58 Phase III psoriasis 58 ARIKACE ™ 58 recurrent GBM 58 PrevOnco ™ 58 thetreatment 58 Combo Stent 58 OncoVEX GM CSF 58 tezampanel NGX# 58 ozarelix 58 CURRENT OASIS 7 58 Mipomersen 58 vitro experiments 58 ocrelizumab 58 therapeutic regimens 58 Cetrorelix